ISRCTN98318971CompletedNot Applicable
A double-blind, placebo controlled study to assess the effects of early intervention and/or treatment with epoetin alfa on anaemia in cancer patients receiving non-platinum containing chemotherapy
Janssen-Cilag Ltd (UK)0 sites0 target enrollmentStarted: August 19, 2002Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Diagnosis of non-myeloid malignancy, which requires non-platinum containing chemotherapy
- •2. Predicted chemotherapy of 12 to 24 weeks (three to six cycles) duration
- •3. Performance score zero to three
- •4. Life expectancy of more than six months
- •5. Aged over 18 years
- •6. Patients with acute leukaemia are excluded
- •7. No myeloablative chemotherapy
- •8. No uncontrolled hypertension
- •9. No evidence of untreated iron, folate or vitamin B12 deficiency
Exclusion Criteria
- •Does not comply with the above inclusion criteria
Investigators
Similar Trials
Active, not recruiting
Phase 1
A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)overactive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-001334-40-GBPLETHORA SOLUTIONS LIMITED112
Active, not recruiting
Not Applicable
A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)overactive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-001334-40-IEPLETHORA SOLUTIONS LIMITED112
Completed
Not Applicable
A double-blind, placebo-controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with symptoms of overactive bladderISRCTN97355181Plethora Solutions Ltd (UK)100
Active, not recruiting
Phase 1
A study to see how inhaled PC945 affects a fungal infection in patients with asthma or other lung diseases.Pulmonary aspergillosis and candidiasis of lungMedDRA version: 20.0Level: LLTClassification code 10059259Term: Pulmonary aspergillosisSystem Organ Class: 100000004862MedDRA version: 20.0Level: LLTClassification code 10007155Term: Candidiasis of lungSystem Organ Class: 100000004862EUCTR2018-000244-26-GBPulmocide Ltd46
Completed
Not Applicable
A double blind, placebo controlled study to assess the safety and efficacy of PCD-04 as a protective agent against anthracycline-induced cardiotoxicity.CancerBreast cancerISRCTN56637853TT Bio-Pharma (Japan)72